Raymond James analyst Tiago Fauth initiated coverage of Milestone Pharmaceuticals (MIST) with a Strong Buy rating and $6 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIST:
- Milestone Pharmaceuticals announces availability of Cardamyst on Express Scripts
- Regulatory Disruptions Pose Material Operational Risks for Milestone Pharmaceuticals
- Milestone: Early CARDAMYST Launch Progress and Solid Cash Position Underscore Buy Rating and $8 Target
- Midday Fly By: FedEx reports ‘beat and raise,’ Ecolab to acquire CoolIT
- Milestone Advances CARDAMYST Launch After Landmark PSVT Approval and Bolsters Cash Runway